Biocon And Amgen Strike Deal, Opening Doors For Bosaya And Aukelso In US Pharma Arena

Biocon Ltd announced a significant step forward in its global expansion plans with the US Food and Drug Administration (FDA) approval and upcoming launch of two biosimilars, Bosaya™ and Aukelso™, starting October 1, 2025. Concurrently, Biocon Biologics has declared a landmark settlement with Amgen, resolving key patent litigations surrounding these products.

Key Highlights Of The Launch And Settlement

Bosaya™ (denosumab-kyqq) and Aukelso™ (denosumab-kyqq) are biosimilars to Amgen’s blockbuster drugs Prolia® and Xgeva®, respectively, approved for osteoporosis and bone-related cancer treatments.

The FDA granted provisional interchangeability designation to both biosimilars, allowing pharmacists to substitute them for branded counterparts.

Bosaya™ is indicated for the treatment of osteoporosis in postmenopausal women and men at high fracture risk, glucocorticoid-induced osteoporosis, and bone loss in cancer patients undergoing hormonal therapy.

Aukelso™ targets prevention of skeletal-related events in multiple myeloma, bone metastases, and specific bone tumor treatments.

The October 1 US launch marks a major commercial milestone for Biocon, tapping into a US market where denosumab sales exceeded $4.9 billion in 2024.

Biocon Biologics has entered a settlement with Amgen over patent disputes, clearing the path for market entry and reducing legal uncertainties.

The settlement is part of a broader trend of biosimilar patent resolutions between Biocon and Amgen, highlighting maturing market dynamics.

Strategic Importance And Future Outlook

The launch strengthens Biocon’s position in the lucrative US biosimilars space and expands patient access to affordable therapies. It also underscores Biocon’s growing global footprint and regulatory prowess.

Sources: Biocon Ltd official releases, Nasdaq, PharmaFocus America